newsfilter
← Latest News
GlobeNewswire·

Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a